Last reviewed · How we verify
Antibiotic oral suppressive therapy
Antibiotic oral suppressive therapy uses low-dose antibiotics taken orally over an extended period to prevent recurrent bacterial infections.
Antibiotic oral suppressive therapy uses low-dose antibiotics taken orally over an extended period to prevent recurrent bacterial infections. Used for Recurrent urinary tract infections (prophylaxis), Recurrent bacterial infections (suppressive therapy).
At a glance
| Generic name | Antibiotic oral suppressive therapy |
|---|---|
| Sponsor | Atlantic Health System |
| Drug class | Antibiotic (suppressive therapy) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This therapeutic approach involves chronic administration of oral antibiotics at sub-therapeutic doses to suppress the growth of pathogenic bacteria and reduce the risk of recurrent infections. It is commonly used in patients with recurrent urinary tract infections, chronic prostatitis, or other conditions prone to bacterial recurrence. The mechanism relies on maintaining suppressive antibiotic levels in tissues and body fluids to prevent bacterial colonization and infection.
Approved indications
- Recurrent urinary tract infections (prophylaxis)
- Recurrent bacterial infections (suppressive therapy)
Common side effects
- Gastrointestinal upset
- Allergic reaction
- Photosensitivity (if fluoroquinolone-based)
- Yeast infection/candidiasis
Key clinical trials
- Proper Duration of Suppressive Antibiotic Therapy After Debridement, Antibiotics, and Implant Retention (NA)
- Treatment of Acute Periprosthetic Joint Infection Comparing Single and Planned Double-Debridement Antibiotics and Implant Retention Followed by Chronic Antibiotic Suppression (NA)
- Long-Term Safety and Efficacy of Moxifloxacin in Bronchiectasis Patients (PHASE3)
- Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study (PHASE2, PHASE3)
- Antibiotic Bladder Instillations vs. Oral Suppression for the Treatment of Recurrent Urinary Tract Infections (PHASE4)
- Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections (PHASE2, PHASE3)
- Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antibiotic oral suppressive therapy CI brief — competitive landscape report
- Antibiotic oral suppressive therapy updates RSS · CI watch RSS
- Atlantic Health System portfolio CI